At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02563 BIOSTAR PHARM-B
Not Yet Opened 01-21 13:40:24
3.720
+0.020
+0.54%
High3.800
Low3.700
Vol7.00K
Open3.700
D1 Closing3.700
Amplitude2.70%
Mkt Cap1.36B
Tradable Cap806.20M
Total Shares364.59M
T/O26.08K
T/O Rate0.00%
Tradable Shares216.72M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BIOSTAR PHARM-B (02563): First Patient Dosed in U.S. Pivotal Clinical Study of Utidelone for Breast Cancer Brain Metastasis
Beijing Biostar Pharmaceuticals Co Ltd is a Chinea-based company principally engaged in the research, development, production and sales of innovative drugs. The Company's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The Company's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The Company mainly conducts its businesses in the domestic market.